Camlin Fine Sciences Ltd

- The company has planned a rights issue in the near future to address liquidity and working capital challenges (Page 4). - The rights issue is intended to recoup losses and support working capital needs (Page 9). - No immediate plans to reduce existing debt, but the company aims not to increase debt further and stabilize business first (Page 4). - Current gross debt is around INR750 crores; net debt approximately INR650 crores; includes short-term working capital of ~INR300 crores and long-term debt of ~INR440 crores (Page 4). - No indication of new debt fundraising currently; focus is on restructuring existing loans, especially in Europe (Page 5). - No specific timeline or quantum mentioned for the rights issue beyond "very near future" (Page 4).

- The company is currently running vanillin capacity at 40% and plans to scale up to 50% in the next year, with an aim to reach 100% utilization eventually. - There are no immediate plans to expand vanillin capacity beyond the existing 6,000 tons. - Focus is on optimizing current capacities before considering further expansion. - No mention of other specific capital expenditures or strategic investments in the near term. - The management is concentrating on growing existing businesses like Blends and Aroma, improving utilization, and awaiting clarity on antidumping duties before entering into long-term contracts or making new investments. - There is mention of restructuring efforts and rights issue planned to strengthen working capital and stabilize the business, not specifically for new capex.

- Blends business expected to grow at ~20% YoY for next couple of years; target to increase revenue from INR220 crores to INR300 crores over 4-5 quarters. - Aroma business planned to ramp up capacity utilization from 40% to 55% by FY '25-end, reaching 75% by FY '26 and eventually 100%; revenue expected to grow from INR40-45 crores to around INR80-100 crores. - Performance Chemicals (hydroquinone, catechol) expected to grow 15-20% in next financial year; current utilization at 80%, with expansion tied to downstream demand. - Blends revenue in Europe about INR18 crores currently with growth focus; aim to increase footprint and volume. - Overall revenue guidance for FY '26 likely around INR2,300-2,400 crores. - EBITDA margins expected to remain in mid-teens, though pricing and market factors make exact margin prediction difficult.

- Revenue for FY '26 is expected to be in the range of INR 2,300 to INR 2,400 crores. - EBITDA margins are anticipated to remain in the teens, with mid-teens possible but difficult to predict due to pricing uncertainties. - EBITDA margins improved to 10.2% in Q2 FY '25, with expectations to maintain or modestly improve margins in H2 FY '25. - Savings from European facility shutdown likely to increase EBITDA margins by about 4% but only after two quarters. - Blends business projected to grow ~20% annually over next few years, supporting top-line growth. - Aroma business capacity utilization expected to rise from current ~40% to 75%-80% by FY '26, reaching full capacity later. - Performance Chemicals segment anticipated to grow 15%-20% with new value-added products. - No further major impairments anticipated; working capital and liquidity remain focus areas. - Rights issue planned to support working capital and stabilize operations.

The transcript does not explicitly provide specific figures or detailed commentary on the current or expected order book or pending orders for Camlin Fine Sciences Limited. However, insights can be inferred: - The company is seeing steady growth in the Blends business with expectations to grow it by about 20% year over year. - Aroma business is improving, currently operating at about 40-50% capacity, aiming to reach 75-80% capacity over the next couple of years, with continued demand. - Confidence expressed about revenue growth for FY '26 around INR 2,300-2,400 crores. - Contracts in Aroma business are typically short-term (quarterly or half-yearly) due to antidumping duty uncertainty, suggesting order visibility is currently short term. - No mention of long-term contracts being signed until antidumping duties are finalized. - The Europe facility shutdown impacts current revenue and EBITDA but is expected to stabilize. No explicit quantitative pending orderbook or backlog figures were disclosed.